Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells.
In conclusion, our results demonstrated that the anthracycline-induced resistance in bladder cancer cells positively correlated with TP53 mutations in the tetramerization domain in J82 and TCCSUP cells. Further, AD 312 and AD 198 are promising chemotherapeutic drugs for bladder cancer, especially in combination with PRIMA-1. PMID: 29983877 [PubMed]
Investigational agent sacituzumab govitecan showed activity in patients with metastatic urothelial cancer, including some previously treated with immune checkpoint inhibitors.Medscape Medical News
The majority of period tracker apps fail women, fitness trackers, and wearables fail pregnant women terribly. They were most probably designed and developed by men, and most likely not consulted by future users. We looked around at the women’s health and “femtech” market and found that digital health technology has yet to live up to female expectations. So far, the area is under-researched, underfunded and not understood. Technology – Still a man’s world In spite of the slogan of diversity pinned on the flag of many tech companies, the field is highly dominated by men. It is easy to ima...
CONCLUSIONS: LncSNHG14 overexpression accelerates proliferative potential and cell cycle progression of BCa cells through absorbing miRNA-150-5p to degrade VAMP2 expression. PMID: 30779068 [PubMed - in process]
CONCLUSIONS: According to the results, we found that lncRNA RMRP was closely related to the progression of bladder cancer, which could be a potential target for treating BC patients. PMID: 30779067 [PubMed - in process]
We would like to thank Scott M. Gilbert for [his] thoughtful examination of this manuscript. As outlined, a major finding of this work is that patients with high-risk nonmuscle invasive bladder cancer (NMIBC) as defined by the European Urological Association and American Urological Association [ref] had significantly worse patient reported outcomes compared to those with nonhigh-risk disease. The survey tools utilized for the Medicare Health Outcomes Survey (MHOS) are not cancer specific instruments, yet still demonstrated statistically and clinically significant decreases in physical and mental health-related quality of life.
In the study “Nonmuscle Invasive Bladder Cancer Influences Physical Health Related Quality of Life and Urinary Incontinence, Wayne G. Brisbane and colleagues examine patient-reported quality of life (QOL) and urinary incontinence outcomes associated with the diagnosis and management of nonmuscle invasive bladd er cancer. The study is based on SEER cancer registry data linked to patient-reported outcomes (PROs) data collected as part of the Medical Health Outcomes Survey (SEER-MHOS), which allowed the authors to not only evaluate patient-reported outcomes in a representative sample of bladder cancer patien ts managed ...
In this study of 991 patients, 794 (80%) patients received an ileal conduit (IC) urinary diversion.
In conclusion, the risk of arterial thromboembolic events begins to increase 150 days before the date of cancer diagnosis in older persons and peaks in the 30 days before.
CONCLUSIONS These results not only reveal new players regulating BCa chemoresistance, but also provide clues for effective chemotherapy for BCa patients. PMID: 30778022 [PubMed - in process]
Publication date: 19 February 2019Source: Cell Reports, Volume 26, Issue 8Author(s): Tadeusz Majewski, Hui Yao, Jolanta Bondaruk, Woonbok Chung, Sangkyou Lee, June Goo Lee, Shizhen Zhang, David Cogdell, Guoliang Yang, Woonyoung Choi, Colin Dinney, H. Barton Grossman, Christopher Logothetis, Steven E. Scherer, Charles C. Guo, Li Zhang, Peng Wei, John N. Weinstein, Jean-Pierre Issa, Keith BaggerlySummaryWe used whole-organ mapping to study the locoregional molecular changes in a human bladder containing multifocal cancer. Widespread DNA methylation changes were identified in the entire mucosa, representing the initial field ...